RxDoctor Payments Data

Abigail Soto, MD

Adult Medicine · San Bernardino, CANPI 1538592506

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 71 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 15 manufacturers reported payments, led by AbbVie at 39.8% of the total. Reporting peaked in 2021 at $614 and has fallen 91.4% since, to $53 in 2024.

$1,271in general payments, 2019–2025

Across 71 payments — averaging $17.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$506
  • Lilly USA, LLC$204
  • Novo Nordisk$153
  • Merck$79
  • Amgen$65
  • Biosense Webster, Inc.$55
  • plus $207 from 9 others

What the payments were for

  • Food & beverage$1,271100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,271 in reported general payments places this provider in the 75th percentile of 221 adult medicine providers in California.

See all adult medicine providers in California

Medicare billing

Part B allowed, 2024
$46,759
Medicare patients
147
Services billed
386

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban24$27,660
OzempicSemaglutide24$20,991
JardianceEmpagliflozin15$15,763
RybelsusSemaglutide13$13,963
JanuviaSitagliptin Phosphate14$13,442
XareltoRivaroxaban11$6,828
Levothyroxine Sodium223$2,582
Atorvastatin Calcium345$2,552
Wixela InhubFluticasone Propion/Salmeterol19$2,178
Duloxetine Hcl41$1,505
Gabapentin76$1,425
Tamsulosin Hcl77$1,149
Losartan Potassium116$1,128
Albuterol Sulfate HfaAlbuterol Sulfate38$1,033
Lisinopril132$996

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$153$34,95337 claims
PfizerEliquis$41$27,66024 claims
Boehringer IngelheimJardiance$13$15,76315 claims
MerckJanuvia$79$13,44214 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 221 adult medicine providers in California.

Other adult medicine in San Bernardino

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →